Cost Analysis Of Type 2 Diabetes Mellitus Therapy In High-Income And Low And Middle-Income Countries: A Systematic Review

Raihana Nurul Izzah; Dwi Endarti; Tri Murti Andayani

doi:10.30595/jhepr.v4i1.202

Authors

Raihana Nurul Izzah Gadjah Mada University
Dwi Endarti Gadjah Mada University https://orcid.org/0000-0001-7841-4164
Tri Murti Andayani Gadjah Mada University https://orcid.org/0000-0003-0075-8260

DOI:

https://doi.org/10.30595/jhepr.v4i1.202

Keywords:

Burden of disease, Complications, Health care costs, Healthy Life-style, Medicines

Abstract

Abstract

Introduction: Diabetes is currently a very serious health problem. There is an increase in the prevalence and incidence of type 2 diabetes mellitus, this disease causes suffering for sufferers and also causes the death of a person, which makes a large economic burden for both the community and health care facilities. This study aimed to analyze the total direct medical costs of type 2 diabetes mellitus therapy in high-income, low- and middle-income countries.

Methods: A systematic review was carried out following the PRISMA guidelines. The article search method was carried out by searching PubMed, ScienceDirect, and Springer for articles that analyzed the total direct medical costs of type 2 diabetes mellitus therapy. Nine articles are considered important to be discussed in this review, these nine articles were published between January 2014 and December 2023.

Result: The results showed that the two components that had the greatest impact on the direct medical costs of managing type 2 diabetes were inpatient services and medications. Direct medical costs ranged from the lowest to the highest at $343,93 for the Kenya study to $5.090,48 for the Spain study, while medication costs ranged from $34,23 for Indonesia to $645,52 for Bangladesh from the average annual direct costs per person. The most widely used drugs were oral hypoglycemic drugs, while the most expensive drugs were Combination of Oral and Insulin. Complications of diabetes resulted in increased expenditure of the total direct medical costs.

Conclusion: This review concludes that the studies reviewed indicate a considerable health financing burden in the care of type 2 diabetes mellitus. Efforts to prevent diabetes complications have the possibility of saving the cost of diabetes care.

Author Biographies

Raihana Nurul Izzah, Gadjah Mada University

Master Program of Pharmacy Management, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia

Dwi Endarti, Gadjah Mada University

Department of Pharmaceutics, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia

Tri Murti Andayani, Gadjah Mada University

Department of Pharmacology & Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia

References

Petersmann, A. et al. Definition , Classification and Diagnosis of Diabetes Mellitus. German Diabetes Association: Clinical Practice Guidelines 127, 1–7 (2019).

Misra, A., Hills, A. P., Soares, M. & Ramaiya, A. A. R. K. L. Diabetes in developing countries. Journal of Diabetes 11, 522–539 (2019).

Khan, M. A. B. et al. Epidemiology of Type 2 Diabetes – Global Burden of Disease and Forecasted Trends. Journal of Epidemiology and Global Health 10, 107–111 (2020).

International Diabetes Federation. Diabetes Atlas, 10th Edition. (International Diabetes Federation, Brussels, Belgium, 2021).

Alfaqeeh, M., Alfian, S. D. & Abdulah, R. Factors Associated with Diabetes Mellitus among Adults: Finding from the Indonesian Family Life Survey-5. Endocrine and Metabolic Science 14, 1–7 (2024).

Tino, S. et al. Prevalence and factors associated with overweight and obesity among patients with type 2 diabetes mellitus in Uganda - A descriptive retrospective study. BMJ Open 10, 1–8 (2020).

Einarson, T. R., Annabel, Ludwig, C. & Panton, U. H. Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review. Elsevier 21, 881–890 (2018).

Ashri, R., Aulia, D. & Siregar, F. A. Analysis of Medical Costs of Type 2 Diabetes Mellitus Outpatient Muhammadiyah Hospital North Sumatra. Jurnal Medicoeticolegal dan Manajemen Rumah Sakit 12, 188–195 (2023).

Jimeno, C. et al. Direct medical costs of type 2 diabetes mellitus in the Philippines: Findings from two hospital databases and physician surveys. BMJ Open 11, (2021).

Li, H., Cai, L. & Golden, A. R. Short-Term Trends in Economic Burden and Catastrophic Costs of Type 2 Diabetes Mellitus in Rural Southwest China. Journal of diabetes research 1–6 (2019).

American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2017. Diabetes Care 41, 917–928 (2018).

Tandah, M. R., Janna, R. R., Mallisa, T. & Diana, K. Analisis Biaya Medis Langsung Dan Tarif Ina-Cbg’s Pasien Diabetes Melitus Tidak Tergantung Insulin Di RSUD Anutapura Palu. Jurnal Ilmiah Ibnu Sina 8, 57–70 (2024).

Pratiwi, A. & Sukmawati, H. Analisis Biaya Rata-Rata Pasien Rawat Inap Dengan Penyakit Diabetes Mellitus Type II (Studi Di Jembrana Dan Gianyar). Jurnal Lingkungan & Pembangunan, Oktober 2019 3, 21–29 (2019).

Seuring, T., Archangelidi, O. & Suhrcke, M. The Economic Costs of Type 2 Diabetes: A Global Systematic Review. PharmacoEconomics 33, 811–831 (2015).

Domeikienė, A., Vaivadaitė, J., Ivanauskienė, R. & Padaiga, Ž. ScienceDirect Direct cost of patients with type 2 diabetes mellitus healthcare and its complications in Lithuania. MEDICINA 50, 54–60 (2014).

Ng, C. S., Paul, M., Sim, H., Ko, Y. & Lee, J. Y. Direct Medical Cost of Type 2 Diabetes in Singapore. PLOS ONE 1–11 (2015).

Mata-Cases, M. et al. Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain. The European journal of health economics 17, 1001–1010 (2015).

Li, X. et al. Direct medical costs for patients with type 2 diabetes in 16 tertiary hospitals in urban China: A multicenter prospective cohort study. Journal of diabetes investigation 10, 539–551 (2019).

Butt, M. D. et al. Cost of Illness Analysis of Type 2 Diabetes Mellitus: The Findings from a Lower-Middle Income Country. International Journal of Environmental Research and Public Health 19, 1–15 (2022).

Afroz, A. et al. Type 2 diabetes mellitus in Bangladesh: a prevalence based cost-of-illness study. BMC health services research 19, 1–12 (2019).

Oyando, R. et al. Patient costs of diabetes mellitus care in public health care facilities in Kenya. John Wiley & Sons Ltd 35, 290–308 (2020).

Pham, H. T. K. et al. Direct medical costs of diabetes and its complications in Vietnam : A national health insurance database study. Diabetes Research and Clinical Practice 162, 1–8 (2020).

Hidayat, B. et al. Direct Medical Cost of Type 2 Diabetes Mellitus and Its Associated Complications in Indonesia. Value in Health Regional Issues 28, 82–89 (2022).

Handelsman, Y. et al. And American College Of Endocrinology – Clinical Practice Guidelines For Developing a Diabetes Mellitus Comprehensive Care Plan. American Association of Clinical Endocrinologists 1–40 (2016).

Zhang, X. et al. Direct medical cost associated with diabetic retinopathy severity in type 2 diabetes in Singapore. PloS one 12, 1–11 (2017).

Kansra, P. & Oberoi, S. Cost of diabetes and its complications: results from a STEPS survey in Punjab, India. Global health research and policy 8, 1–11 (2023).

Kansra, P. Biaya diabetes dan komplikasinya : hasil survei STEPS di Punjab , India. 8, 1–11 (2023).

Bermudez-Tamayo, C. et al. Direct and indirect costs of diabetes mellitus in Mali: A case-control study. PLOS ONE 1–14 (2017).

Wu, H. et al. Direct medical cost of diabetes in rural China using electronic insurance claims data and diabetes management data. Journal of diabetes investigation 10, 531–538 (2019).

Ko, S.-H. et al. Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002 – 2013. MEDICINE 1–7 (2016).

Rowley, W. R., Bezold, C., Arikan, Y., Byrne, E. & Krohe, S. Diabetes 2030: Insights from Yesterday, Today, and Future Trends. Population Health Management 20, 6–12 (2017).

Zhuo, X. et al. The Lifetime Cost of Diabetes and Its Implications for Diabetes Prevention. Diabetes Care 37, 2557–2565 (2014).

Owens, D. R., Monnier, L. & Barnett, A. H. Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy. Diabetes, Obesity and Metabolism 19, 1339–1352 (2017).